Journal
FUTURE VIROLOGY
Volume 8, Issue 11, Pages 1085-1094Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fvl.13.98
Keywords
antiviral; drug combination; drug resistance; favipiravir; H1N1; influenza; mice; oseltamivir; T-705; treatment
Categories
Funding
- Virology Branch [HHSN272201000039I]
- Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, USA
- [N01-AI-30063]
Ask authors/readers for more resources
Aim: Favipiravir and oseltamivir are antiviral compounds used for the treatment of influenza infections. We have aimed to investigate the efficacy of the compounds in combination to treat influenza H1N1 virus infections in mice. Materials & methods: Mice infected with pandemic influenza A/California/04/2009 (H1N1pdm) virus or an oseltamivir-resistant (H275Y neuraminidase mutation) influenza A/Mississippi/3/2001 (H1N1) virus were treated orally with inhibitors twice a day for 5 days starting 4 h after infection. Results: Complete protection from death was afforded by favipiravir treatments of 100 mg/kg/day, but lower doses were less effective. Combinations of oseltamivir (1 and 3 mg/kg/day) with favipiravir (3, 10 and 30 mg/kg/day) resulted in a synergistic improvement in survival rates against H1N1pdm infections. Significant reductions in lung virus titers also occurred. Against the H275Y virus infection, oseltamivir alone was only 30% protective from death at 100 mg/kg/day, but combinations of the two compounds produced a synergistic improvement in survival rate. Conclusion: The utility of treating H1N1 influenza virus infections with oseltamivir and favipiravir in combination has been established.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available